Mode
Text Size
Log in / Sign up
Phase 4 N=15 Single-blind Treatment

An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder

Irritable Bowel Syndrome · Generalized Anxiety Disorder

Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Jul 2014
Primary outcome: Primary: Clinical Global Impression Scale — 2.64 scores on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Duloxetine (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
West Penn Allegheny Health System
Primary completion
Dec 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Clinical Global Impression Scale
2.64
SECONDARY
Hamilton Anxiety Rating Scale
9.75
SECONDARY
Irritable Bowel Syndrome-Quality of Life Scale
81.73
SECONDARY
Irritable Bowel Syndrome Severity Scoring System
187.09

Summary

The investigators propose to evaluate the effectiveness of duloxetine in treating subjects with both Irritable Bowel Syndrome (IBS) and Generalized Anxiety Disorder (GAD). The investigators hypothesize that duloxetine as a single therapeutic agent will effectively target pain and other core symptoms of IBS as well as GAD in this patient population with both conditions.

Eligibility Criteria

Inclusion Criteria

  • 18-65 years of age
  • Active IBS diagnosis by a gastroenterologist
  • Generalized Anxiety Disorder diagnosed by DSM-IV TR criteria and the Mini International Neuropsychiatric Interview for the DSM-IV (Mini)
  • No changes in any non study medication once starting the study

Exclusion Criteria

  • Current diagnoses of Major Depressive Disorder, Panic Disorder, Social Phobia, Post Traumatic Stress Disorder, Obsessive Compulsive Disorders, Eating Disorders, Somatoform Disorders, Drug or alcohol abuse or dependence, or severe personality disorder
  • Lifetime history of any Bipolar Disorder or Psychotic Disorder
  • Concurrent GI disorders falling outside of Rome III Functional GI disorders
  • Pregnant women or sexually active female subjects not using medically acceptable method of contraception
  • Current suicidal ideation
  • Unstable medical condition
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00961298). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search